Detalhe da pesquisa
1.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028407
2.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol
; 16(3): 257-65, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25704439
3.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med
; 366(3): 207-15, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22256804
4.
Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas.
Mod Pathol
; 22(1): 142-50, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18997735
5.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
J Clin Oncol
; 37(12): 992-1000, 2019 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30785829
6.
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Clin Cancer Res
; 23(18): 5394-5405, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916617
7.
Trichosporon pullulans as a complication of chronic granulomatous disease in a patient undergoing immunosuppressive therapy for inflammatory bowel disease.
Pediatr Infect Dis J
; 25(1): 87-9, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16395115
8.
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.
J Immunother Cancer
; 4: 72, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27879974
9.
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.
Target Oncol
; 11(2): 149-56, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26310975
10.
RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system.
Thromb Haemost
; 93(1): 106-14, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15630499
11.
Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery.
J Control Release
; 78(1-3): 235-47, 2002 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-11772464
12.
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Cancer Res
; 72(3): 779-89, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22180495
13.
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Cancer Res
; 72(4): 969-78, 2012 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22205714
14.
An unusual case of gastrointestinal bleeding.
Case Rep Pediatr
; 2011: 748543, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22606522
15.
Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Cancer Biol Ther
; 8(16): 1587-95, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19556859
16.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
New Engl. J. Med
; 373: 123-135, julio, 2015.
Artigo
em Inglês
| URUCAN | ID: bcc-5148